Description
Pomalidomide is sold by Celgene Inc., in the USA, under the brand name Pomalyst. Pomalidomide is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma (a type of blood cancer) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. Pomalidomide is available under the name of Pomalid and is available in 3 different powers which are as follows Pomalid 1MG, 2MG, and 4MG.
| Strength | 2 mg |
| Pack Size | 21 Capsule |
| Brand | Pomalid |
| Packaging Type | Box |
| Composition | Not specified |
| Form | Not specified |
| Shelf Life | Not specified |
| Usages | Not specified |
| Country of Origin | Not specified |








